Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

728
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
728

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood biomarkers predict conversion from cognitively stable to mild cognitive impairment or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Frontal Release Signs and Future Decline in Research Participants With Intact Cognition.

JAMA network open·2026
Same author

Frequency of mixed neuropathologies in individuals with down syndrome with and without Alzheimer's dementia.

Acta neuropathologica·2026
Same author

The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Apr 15, 2026

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

13.0K

A practical algorithm for managing Alzheimer's disease: what, when, and why?

Jeffrey L Cummings1, Richard S Isaacson2, Frederick A Schmitt3

  • 1Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada and Cleveland, Ohio.

Annals of Clinical and Translational Neurology
|March 28, 2015
PubMed
Summary

Alzheimer's disease (AD) management involves lifestyle changes and pharmacologic therapies like cholinesterase inhibitors (ChEIs) and memantine. Early diagnosis and individualized treatment plans are crucial for supporting patients and caregivers.

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.6K

Related Experiment Videos

Last Updated: Apr 15, 2026

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

13.0K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.6K

Area of Science:

  • Neurology
  • Geriatrics
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a progressive dementia with increasing prevalence.
  • Effective management strategies are vital for patients and caregivers across the disease continuum.

Purpose of the Study:

  • To outline current approaches to Alzheimer's disease management.
  • To detail pharmacologic and non-pharmacologic interventions for AD.
  • To emphasize individualized care and caregiver support.

Main Methods:

  • Review of current therapeutic options for Alzheimer's disease.
  • Discussion of lifestyle modifications, pharmacologic agents, and supportive care.

Main Results:

  • Lifestyle factors (diet, exercise, social engagement) may reduce AD risk and slow cognitive decline.
  • Cholinesterase inhibitors (ChEIs) improve cognition and daily function in mild-to-moderate AD.
  • Memantine is approved for moderate-to-severe AD, and treatment choice depends on individual patient needs.

Conclusions:

  • Individualized pharmacologic and non-pharmacologic interventions are key to managing Alzheimer's disease.
  • Ongoing monitoring, comorbidity management, and robust caregiver support are essential.
  • Treatment decisions should consider patient preference, tolerability, and cost.